Cognos Co-Founder and CIO Josh Shachar Discusses The Evolution of the Cognos Vision

2NOVEMBER, 2021Co-Founder and CIO Josh Shachar Discusses the Evolution of the Cognos Vision In a recent presentation to the Cognos Shareholders, Josh Shachar, the Co-Founder and Chief Innovation Officer for Cognos Therapeutics presented a compelling vision for the...

Cognos Engages Maxim Group for Investment Banking and Financial Advisory Services

Cognos Therapeutics Corp. Engages Maxim Group LLC for Investment Banking and Financial Advisory Services Cognos Therapeutics has signed a Letter of Engagement to retain Maxim Group LLC (“Maxim”) to provide financial advisory and investment banking services, including...

Cognos Announces Addition of New Clean Room To Expand Its Development Capabilites.

28OCTOBER, 2021Cognos Announces Addition of New Clean Room To Expand Its Development Capabilities Cognos Therapeutics announced today the addition of an ISO-7 Clean Room to their existing Los Angeles laboratory facility (WATCH THE OVERVIEW VIDEO NOW). The clean...

Dr. Susan Alpert, MD, PhD, Joins Cognos Therapeutics as Lead Regulatory Consultant

27 FEBRUARY, 2019 Dr. Susan Alpert, MD, PhD, Joins Cognos Therapeutics as Lead Regulatory Consultant Dr. Susan Alpert, MD, PhD, has been named Lead Regulatory Consultant for Cognos Therapeutics, Inc. Dr. Alpert is considered one of the top U.S. regulatory ­­­experts....

Cognos’ SINNAIS Smart Implantable Pump to Improve CAR T Cell Efficacy in Solid tumors

11 JANUARY, 2018 Cognos' SINNAIS Smart Implantable Pump has potential to Improve CAR T Cell Efficacy in Solid Tumors Cognos Therapeutics (Cognos Thx) is exploring the potential of using its SINNAIS implantable pump as the delivery mechanism for a new drug therapy...

Cognos Therapeutics plans to conduct a twenty-patient human clinical trial using direct delivery of Herceptin (a Genentech drug) to prove drug safety in the brain region.

13 JULY, 2017 Cognos Therapeutics plans to conduct a twenty-patient human clinical trial using direct delivery of Herceptin (a Genentech drug) to prove drug safety in the brain region. Cognos Therapeutics (Cognos Thx) plans to use Herceptin, a Genentech drug, to be...

Dr. Francis Ali-Osman

16 SEPT, 2016 Dr. Francis Ali-Osman Discusses Future of Cancer Treatment On September 16, 2016 Dr. Francis Ali-Osman was asked to speak at the Hancock Symposium at Westminster Collage on the state of cancer research and treatment. During his talk, Dr. Ali-Ozman...

FDA’s Role In The Precision Medicine Initiative Pushes Combination Drug Devices to New Heights Sharing Cognos Therapeutics Vision.

31 MAR, 2015 FDA's Role In The Precision Medicine Initiative Pushes Combination Drug Devices to New Heights Sharing Cognos Therapeutics' Vision. Most medical treatments are designed for the "average patient" as a “one-size-fits-all approach”, that is successful for...

NEWS and INFORMATION

The following posts and articles are for information only regarding advancements in our technology and business as well as relevant articles on the state of research and important voices of authority in the medical community.

Dr. Francis Ali-Osman

Dr. Francis Ali-Osman

Dr. Francis Ali-Osman speaks at the Hancock Symposium at Westminster Collage on the state of cancer research and treatment.

read more